Publications by authors named "Jane Estell"

Claim this Profile
C
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.
Slavisa Ninkovic, Simon J Harrison, Je-Jung Lee, Nick Murphy, Jae Hoon Lee, Jane Estell

Haematologica· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.
Torben Plesner, Simon J Harrison, Hang Quach, Cindy Lee, Adam Bryant, Jane Estell

Clin Hematol Int· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma.
Christa Ellen Nath, Andrew Grigg, Sebastian P A Rosser, Jane Estell, Elizabeth Newman

Eur J Clin Pharmacol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, P Joy Ho, Peter Mollee, Jane Estell

Haematologica· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Maria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, Ajay K Nooka, Jane A Estell

Clin Lymphoma Myeloma Leuk· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
C Ola Landgren, Ajai Chari, Yael C Cohen, Andrew Spencer, Peter Voorhees, Jane A Estell

Leukemia· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
Emmanuel Bachy, John F Seymour, Pierre Feugier, Fritz Offner, Armando López-Guillermo, Jane A Estell

J Clin Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Emmanuel Bachy, Matthew J Maurer, Thomas M Habermann, Bénédicte Gelas-Dore, Delphine Maucort-Boulch, Jane A Estell

Blood· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.
Judith Trotman, Jimmy Trinh, Yiu Lam Kwan, Jane A Estell, Julie Fletcher

Intern Med J· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
Emmanuel Bachy, Jane A Estell, Eric Van de Neste, Réda Bouabdallah, Joan Bargay

Am J Hematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Case of Symptomatic BK Viraemia in a Patient Undergoing Treatment for Hodgkin Lymphoma.
Jacinta Perram, Jane Estell

Case Rep Infect Dis· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
Judith Trotman, Marion Fournier, Thierry Lamy, John Francis Seymour, Anne Sonet, Jane Estell

J Clin Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Gilles Salles, John Francis Seymour, Fritz Offner, Armando López-Guillermo, David Belada, Jane A Estell

Lancet· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis.
Emmanuel J Favaloro, David Patterson, Anna Denholm, Scott Mead, Ann Gilbert, Jane Estell

Br J Haematol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis